Hong W S, Kim C M, Lee J O, Kang T W, Yun T K, Kim C Y
Department of Internal Medicine, Korea Cancer Center Hospital, Nowon-ku, Seoul.
Jpn J Clin Oncol. 1990 Mar;20(1):87-93.
The cytotoxicities of peripheral blood lymphocytes (PBL) and lymphokine-activated killer (LAK) cells were studied to evaluate the effect of chemotherapy on cellular immunity, in 18 patients with unresectable stomach cancer before and after chemotherapy with 5-fluorouracil, adriamycin and mitomycin-C (FAM), and in 21 healthy volunteers. LAK cells were generated in vitro by culturing PBL with 100 U recombinant human interleukin-2 (rH-IL-2)/ml for 72 h. K562 (human myelogenous leukemia), MKN-45 (human stomach adenocarcinoma) and PC-14 (human pulmonary adenocarcinoma) were used as target cells. The cytotoxicity of PBL to K562 and MKN-45 was suppressed in patients with stomach cancer before chemotherapy, compared with that in healthy volunteers (P less than 0.05). The cytotoxicity of LAK cells was significantly higher to all three cell lines tested than that of PBL in both the healthy volunteers and stomach cancer patients (P less than 0.01); however, a lower level of LAK activity was generated in patients with cancer compared to that in the healthy volunteers. FAM therapy did not suppress the cytotoxicities of PBL and LAK cells. The surface markers of PBL and LAK cells were measured, demonstrating that there was no significant change in the percentage of lymphocytes with CD3+, CD4+, CD8+, CD16+ or CD19+ after chemotherapy. The ratios of CD4+ to CD8+ cells in PBL and LAK cells were also not significantly changed after chemotherapy. In the present study, we have demonstrated that the PBL of stomach cancer were defective in generating LAK activity compared to those of controls, but the LAK activity generated from PBL receiving chemotherapy was similar to that from PBL without chemotherapy in stomach cancer patients.
为评估化疗对细胞免疫的影响，研究了18例不可切除胃癌患者及21名健康志愿者外周血淋巴细胞（PBL）和淋巴因子激活的杀伤（LAK）细胞的细胞毒性。这些胃癌患者在接受由5-氟尿嘧啶、阿霉素和丝裂霉素-C（FAM）组成的化疗方案前后进行了检测。通过将PBL与100 U/ml重组人白细胞介素-2（rH-IL-2）体外培养72小时来产生LAK细胞。使用K562（人髓性白血病细胞）、MKN-45（人胃腺癌细胞）和PC-14（人肺腺癌细胞）作为靶细胞。与健康志愿者相比，胃癌患者化疗前PBL对K562和MKN-45的细胞毒性受到抑制（P<0.05）。在健康志愿者和胃癌患者中，LAK细胞对所有三种测试细胞系的细胞毒性均显著高于PBL（P<0.01）；然而，与健康志愿者相比，癌症患者产生的LAK活性水平较低。FAM疗法并未抑制PBL和LAK细胞的细胞毒性。对PBL和LAK细胞的表面标志物进行了检测，结果表明化疗后CD3+、CD4+、CD8+、CD16+或CD19+淋巴细胞百分比无显著变化。化疗后PBL和LAK细胞中CD4+与CD8+细胞的比例也无显著变化。在本研究中，我们证明与对照组相比，胃癌患者的PBL在产生LAK活性方面存在缺陷，但接受化疗的胃癌患者PBL产生的LAK活性与未接受化疗的PBL相似。
